Skip to main content
main-content

19-02-2021 | ASCO GU 2021 | Conference coverage | Video

TIVO-3 results point to tivozanib activity after RCC progression on axitinib

Brian Rini describes an analysis of the TIVO-3 advanced renal cell carcinoma trial suggesting that tivozanib offers better outcomes than sorafenib even in patients who have previously received axitinib (4:07).

Read transcript

Image Credits